MOREPEN LABORATORIES
|
MOREPEN LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.76 | 2.13 | 2.16 | 0.75 | 0.64 |
| CEPS(Rs) | 1.30 | 2.71 | 2.83 | 1.57 | 1.53 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 14.73 | 11.56 | 8.47 | 6.32 | 5.63 |
| Tax Rate(%) | 30.63 | 19.75 | 1.44 | 14.14 | 1.15 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 5.61 | 8.84 | 9.98 | 8.03 | 8.79 |
| EBIT Margin(%) | 4.07 | 8.35 | 8.44 | 4.82 | 4.07 |
| Pre Tax Margin(%) | 3.93 | 8.19 | 8.29 | 4.58 | 3.80 |
| PAT Margin (%) | 2.73 | 6.57 | 8.17 | 3.94 | 3.75 |
| Cash Profit Margin (%) | 4.70 | 8.36 | 10.72 | 8.26 | 8.94 |
| Performance Ratios | |||||
| ROA(%) | 3.55 | 10.55 | 12.76 | 5.25 | 4.80 |
| ROE(%) | 5.93 | 21.79 | 29.20 | 12.50 | 12.04 |
| ROCE(%) | 8.40 | 24.86 | 27.13 | 12.05 | 10.01 |
| Asset Turnover(x) | 1.30 | 1.60 | 1.56 | 1.33 | 1.28 |
| Sales/Fixed Asset(x) | 2.23 | 2.49 | 1.72 | 1.04 | 0.82 |
| Working Capital/Sales(x) | 3.26 | 5.57 | 9.66 | 41.15 | -19.36 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.40 | 0.58 | 0.96 | 1.23 |
| Receivable days | 66.16 | 51.04 | 49.10 | 58.07 | 60.70 |
| Inventory Days | 64.98 | 53.23 | 48.20 | 49.78 | 40.63 |
| Payable days | 98.32 | 86.93 | 94.60 | 118.53 | 130.66 |
| Valuation Parameters | |||||
| PER(x) | 33.94 | 17.20 | 14.89 | 12.78 | 26.89 |
| PCE(x) | 19.71 | 13.52 | 11.35 | 6.09 | 11.29 |
| Price/Book(x) | 1.74 | 3.17 | 3.80 | 1.51 | 3.07 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.90 | 1.11 | 1.17 | 0.47 | 1.14 |
| EV/Core EBITDA(x) | 14.96 | 10.98 | 10.68 | 5.18 | 12.30 |
| EV/EBIT(x) | 22.20 | 13.33 | 13.91 | 9.82 | 27.98 |
| EV/CE(x) | 1.15 | 1.61 | 1.63 | 0.61 | 1.42 |
| M Cap / Sales | 0.93 | 1.13 | 1.22 | 0.50 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -8.36 | 30.20 | 39.27 | 11.00 | 26.72 |
| Core EBITDA Growth(%) | -45.36 | 20.05 | 67.42 | 9.56 | 4.00 |
| EBIT Growth(%) | -55.29 | 28.74 | 144.09 | 31.34 | -8.33 |
| PAT Growth(%) | -61.96 | 4.73 | 189.14 | 16.43 | -3.13 |
| EPS Growth(%) | -64.44 | -1.40 | 189.14 | 16.39 | -2.51 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.04 | 0.05 | 0.52 |
| Current Ratio(x) | 2.35 | 1.61 | 1.30 | 1.06 | 0.88 |
| Quick Ratio(x) | 1.64 | 1.00 | 0.87 | 0.66 | 0.61 |
| Interest Cover(x) | 29.15 | 53.22 | 56.09 | 20.71 | 14.83 |
| Total Debt/Mcap(x) | 0.02 | 0.01 | 0.01 | 0.03 | 0.17 |
Compare Financial Ratios of peers of MOREPEN LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MOREPEN LABORATORIES | ₹2,619.9 Cr | 2.4% | -21.3% | 72.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
MOREPEN LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MOREPEN LABORATORIES | 2.4% |
-21.3% |
72.3% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
